{"nctId":"NCT00976716","briefTitle":"An Open-Label Study Of Celecoxib In Patients With Posttraumatic Pain","startDateStruct":{"date":"2009-09"},"conditions":["Pain"],"count":80,"armGroups":[{"label":"Celecoxib","type":"EXPERIMENTAL","interventionNames":["Drug: Celecoxib"]}],"interventions":[{"name":"Celecoxib","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients with posttraumatic pain which is able to be controlled with an oral NSAID\n* Patients with \"pain\" that meets both of the following criteria within 48 hours after injury:\n\n\"Pain\" Pain intensity (Categorical): \"Moderate pain\" or \"Severe pain\" Pain intensity (VAS): 45.0 mm or more\n\n* Patients with \"inflammation\" that meets the following criteria within 48 hours after injury.\n\n\"Inflammation\" Categorical: \"Mild\", \"Moderate\" or \"Severe\"\n\nExclusion Criteria:\n\n* Patients who have received analgesics and anaesthetics for injury\n* Patients with a history/complication of aspirin-induced asthma\n* Patients taking excluded medications\n* Patients with a history/complication of ischaemic heart disease, serious cardiac arrhythmias, cardiac failure congestive and cerebrovascular disorder or with a history/plan of revascularization","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Patient Impressions at Final Visit (the Number of Participants Who Have Rated \"Excellent\" and \"Good\")","description":"The patient impression of the study medication was entered in the patient diary based on the following categories: \"excellent,\" \"good,\" \"fair\" and \"poor.\"\n\nEfficacy was based on the patient impression of the study medication (\"excellent\" and \"good\") from the first study medication until Final Visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"70","spread":null}]}]}]},{"type":"SECONDARY","title":"Patient Impressions Within 8 Days Post-first Dose (the Number of Subjects Who Have Rated \"Excellent\" and \"Good\")","description":"The patient impression of the study medication was entered in the patient diary based on the following categories: \"excellent,\" \"good,\" \"fair\" and \"poor.\"\n\nEfficacy was based on the patient impression of the study medication (\"excellent\" and \"good\") from the first study medication until each time point.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"44","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60","spread":null}]}]}]},{"type":"SECONDARY","title":"Pain Intensity (PI) of Pain at Rest (Spontaneous Pain) as Measured by Visual Analog Scale (VAS) Within 8 Days Post-first Dose","description":"The PI of pain at rest (spontaneous pain) was recorded on the 100 mm VAS in the patient diary, where 0 mm=no pain, 100 mm=worst possible pain.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"59.9","spread":"11.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47.3","spread":"19.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42.5","spread":"20.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40.3","spread":"20.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38.1","spread":"20.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34.8","spread":"21.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29.0","spread":"22.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.8","spread":"20.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.8","spread":"19.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.4","spread":"19.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.8","spread":"18.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.3","spread":"18.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.0","spread":"18.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.4","spread":"17.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.6","spread":"17.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.3","spread":"18.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.7","spread":"16.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.6","spread":"13.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.2","spread":"13.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.3","spread":"13.4"}]}]}]},{"type":"SECONDARY","title":"PI of Pain on Active Movement as Measured by VAS Within 8 Days Post-first Dose","description":"The PI of pain on active movement was recorded on the 100 mm VAS in the patient diary, where 0 mm=no pain, 100 mm=worst possible pain.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"75.5","spread":"12.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"61.4","spread":"20.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55.3","spread":"21.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51.5","spread":"20.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49.3","spread":"21.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45.5","spread":"21.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39.7","spread":"22.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.5","spread":"22.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32.4","spread":"21.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.2","spread":"22.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26.4","spread":"21.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.5","spread":"21.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.2","spread":"22.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.2","spread":"20.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.2","spread":"20.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.1","spread":"21.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.5","spread":"20.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.3","spread":"20.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.1","spread":"18.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.8","spread":"18.7"}]}]}]},{"type":"SECONDARY","title":"Pain Intensity Differences (PID) in Pain at Rest (Spontaneous Pain) Within 8 Days Post-first Dose","description":"The PID score was obtained by subtracting the PI (by VAS: 0 mm=no pain, 100 mm=worst possible pain) at each time point from the Baseline PI score. Increase in PID scores indicated a lessening of subjects' pain compared to baseline scores; higher scores indicated a greater reduction in pain.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.6","spread":"14.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.4","spread":"16.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.6","spread":"16.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.8","spread":"16.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25.1","spread":"19.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.9","spread":"20.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.1","spread":"18.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37.9","spread":"18.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41.3","spread":"19.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41.8","spread":"19.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44.3","spread":"18.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45.4","spread":"19.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48.0","spread":"17.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48.8","spread":"18.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49.2","spread":"19.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.2","spread":"18.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51.3","spread":"17.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52.4","spread":"15.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52.6","spread":"15.2"}]}]}]},{"type":"SECONDARY","title":"PID in Pain on Active Movement Within 8 Days Post-first Dose","description":"The PID score was obtained by subtracting the PI at each time point from the Baseline PI score. Increase in scores indicated a lessening of subjects' pain compared to baseline scores; higher scores indicated a greater reduction in pain.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.3","spread":"16.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.4","spread":"17.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.3","spread":"17.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26.5","spread":"17.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.3","spread":"19.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.1","spread":"22.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40.2","spread":"21.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43.2","spread":"21.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48.5","spread":"22.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49.5","spread":"20.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52.5","spread":"20.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53.5","spread":"21.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"57.5","spread":"19.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"58.4","spread":"19.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"59.6","spread":"21.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62.1","spread":"20.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"63.3","spread":"20.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"63.6","spread":"18.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"63.7","spread":"18.1"}]}]}]},{"type":"SECONDARY","title":"Sum of Pain Intensity Differences (SPID) for Pain at Rest (Spontaneous Pain) and on Active Movement Until 6 Hours Post-first Dose","description":"The SPID was derived according to the following rule: each PID was weighted by the width of time interval between previous and current time points in hours and summed up to 6 hours post-first dose","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"99.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"118.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Peak Pain Intensity Difference (PPID) for Pain at Rest (Spontaneous Pain) and on Active Movement Until 6 Hours Post-first Dose","description":"The PPID was obtained by subtracting the maximum value of pain intensity (PI) at a time point among 2 to 6 hours post first dose from baseline value of PI for each patient.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Severity of Inflammatory Symptoms (Swelling) Within 8 Days Post-first Dose","description":"The investigator assessed the swelling, using the categories \"None,\" \"Mild,\" \"Moderate,\" and \"Severe\" at Baseline, Visit 2 (Day 4), Visit 3 (Day 8) and Final Visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"69","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Severity of Inflammatory Symptoms (Redness) Within 8 Days Post-first Dose","description":"The investigator assessed the redness, using the categories \"None,\" \"Mild,\" \"Moderate,\" and \"Severe\" at Baseline, Visit 2 (Day 4), Visit 3 (Day 8) and Final Visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"73","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Severity of Inflammatory Symptoms (Localized Warmth) Within 8 Days Post First Dose","description":"The investigator assessed the localized warmth, using the categories \"None,\" \"Mild,\" \"Moderate,\" and \"Severe\" at Baseline, Visit 2 (Day 4), Visit 3 (Day 8) and Final Visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"63","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"66","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Withdrawal Due to Lack of Efficacy","description":"The number of subjects who withdrew due to insufficient clinical response was evaluated.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Summary of Adverse Events","description":"The number of subjects who experienced adverse events (AEs; all-causality and treatment-related) based on safety assessment was summarized. The severity and seriousness of treatment-emergent AEs as well as discontinuations, dose reductions and temporary discontinuations (DR/TD) due to treatment-emergent AEs were also summarized.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":80},"commonTop":["Beta 2 microglobulin urine increased","Beta-N-acetyl-D-glucosaminidase increased","Blood creatine phosphokinase increased","Blood lactate dehydrogenase increased","Diarrhoea"]}}}